EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Nicotine Addiction - Pipeline Review, H1 2017

  • ID: 4115119
  • Report
  • March 2017
  • 57 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Astraea Therapeutics LLC
  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Hager Biosciences LLC
  • Heptares Therapeutics Ltd
  • MORE
Nicotine Addiction - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Astraea Therapeutics LLC
  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Hager Biosciences LLC
  • Heptares Therapeutics Ltd
  • MORE
Introduction

Nicotine Addiction - Overview

Nicotine Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotine Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotine Addiction - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Astraea Therapeutics LLC

C4X Discovery Holdings PLC

Chronos Therapeutics Ltd

CV Sciences Inc

Hager Biosciences LLC

Heptares Therapeutics Ltd

Omeros Corp

Savant HWP Inc

Nicotine Addiction - Drug Profiles

(cannabidiol + nicotine bitartrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotine Addiction - Dormant Projects

Nicotine Addiction - Discontinued Products

Nicotine Addiction - Product Development Milestones

Featured News & Press Releases

May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development

Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine

May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Nicotine Addiction, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1

Nicotine Addiction - Pipeline by Astraea Therapeutics LLC, H1

Nicotine Addiction - Pipeline by C4X Discovery Holdings PLC, H1

Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H1

Nicotine Addiction - Pipeline by CV Sciences Inc, H1

Nicotine Addiction - Pipeline by Hager Biosciences LLC, H1

Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd, H1

Nicotine Addiction - Pipeline by Omeros Corp, H1

Nicotine Addiction - Pipeline by Savant HWP Inc, H1

Nicotine Addiction - Dormant Projects, H1

Nicotine Addiction - Discontinued Products, H1

List of Figures:

Number of Products under Development for Nicotine Addiction, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Addex Therapeutics Ltd
  • Astraea Therapeutics LLC
  • C4X Discovery Holdings PLC
  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Hager Biosciences LLC
  • Heptares Therapeutics Ltd
  • Omeros Corp
  • Savant HWP Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll